



Editas Medicine Reports Inducement Grants to New Chief Financial Officer

January 10, 2020

CAMBRIDGE, Mass., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company's newly appointed Chief Financial Officer, Michelle Robertson. In connection with Ms. Robertson's appointment, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to Ms. Robertson as inducements material to Ms. Robertson entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 120,000 shares of Editas Medicine common stock at a price of \$30.65 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. Robertson's employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Ms. Robertson's continued service relationship with Editas Medicine through the applicable vesting dates. The restricted stock unit award is for 20,000 shares of Editas Medicine common stock and vests as to 25 percent of the shares on each one-year anniversary of Ms. Robertson's employment start date until the fourth anniversary of Ms. Robertson's employment start date, subject to Ms. Robertson's continued service to Editas Medicine through the applicable vesting dates.

About Editas Medicine

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:

Media

Cristi Barnett

(617) 401-0113

cristi.barnett@editasmed.com

Investors

Mark Mullikin

(617) 401-9083

mark.mullikin@editasmed.com



Source: Editas Medicine, Inc.